BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31783768)

  • 1. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.
    Miraldi Utz V; Bulas S; Lopper S; Fenchel M; Sa T; Mehta M; Ash D; Lovell DJ; Kaufman AH
    Pediatr Rheumatol Online J; 2019 Nov; 17(1):79. PubMed ID: 31783768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
    Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study.
    Aeschlimann FA; Angst F; Hofer KD; Cannizzaro Schneider E; Schroeder-Kohler S; Lauener R; van der Kleij D; Rispens T; Saurenmann RK
    J Rheumatol; 2017 Mar; 44(3):334-341. PubMed ID: 28089968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years.
    Aeschlimann FA; Hofer KD; Cannizzaro Schneider E; Schroeder S; Lauener R; Saurenmann RK
    J Rheumatol; 2014 Jul; 41(7):1409-15. PubMed ID: 24833759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 10. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis.
    Cheung CSY; Mireskandari K; Ali A; Silverman E; Tehrani N
    Br J Ophthalmol; 2020 Jul; 104(7):938-942. PubMed ID: 31604701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL; Atienza-Mateo B; Calvo-Rio V; Beltrán E; Sánchez-Bursón J; Adán A; Hernández-Garfella M; Valls-Pascual E; Sellas-Fernández A; Ortego N; Maíz O; Torre I; Fernández-Espartero C; Jovani V; Peiteado D; Valle DD; Aurrecoechea E; Caracuel MA; García-González AJ; Álvarez ER; Vegas-Revenga N; Demetrio-Pablo R; Castañeda S; González-Gay MA; Hernández JL; Blanco R;
    J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
    Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
    Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
    Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
    Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High doses of infliximab in the management of juvenile idiopathic arthritis.
    Tambralli A; Beukelman T; Weiser P; Atkinson TP; Cron RQ; Stoll ML
    J Rheumatol; 2013 Oct; 40(10):1749-55. PubMed ID: 23950184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.
    McCracken C; Yeh S; Jenkins K; Travers C; Stryker D; Tommasello S; Rouster-Stevens KA; Lambert SR; Prahalad S; Drews-Botsch C; Angeles-Han ST
    Eye (Lond); 2019 Apr; 33(4):629-639. PubMed ID: 30487588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.
    Sözeri B; Kardeş E; Salı E; Çakır D; Demir F
    Clin Exp Rheumatol; 2021; 39(4):907-912. PubMed ID: 33635217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.